MedTrace Logo

JSP191 (briquilimab) in Subjects with LR-MDS

NCT05903274 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-02-27

No results posted yet for this study

Summary

A Phase 1 study in subjects with LR-MDS to assess the safety and tolerability of JSP191 as a second-line therapy.

Conditions

  • Lower-risk Myelodysplastic Syndrome

Interventions

DRUG

JSP191

Subjects will receive intravenous JSP191

Sponsors & Collaborators

  • Jasper Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Jasper Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-19
Primary Completion
2024-10-21
Completion
2024-10-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05903274 on ClinicalTrials.gov